Search - tctmd.com

Displaying 461 - 480 of 642

Sort: Relevancy | Date

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

News Daily News

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

April 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

Presentation Fellows 2014

Stent Thrombosis and Restenosis

Presenter: Ajay Kirtane

April 13, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

Presentation Physiology and Intravascular Imaging 2014

Mechanisms and Predictors of In-stent Restenosis and Stent Thrombosis

Presenter: Soo-Jin Kang

March 27, 2014

Presentation

Lack of Association Between DAPT Use and Stent Thrombosis Between 1 and 12 Months Following Resolute ZES Implantation

Presenter: 115704|Sigmund Silber

February 17, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Daily News

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

February 12, 2014

News Daily News

Stent Malapposition Frequent, But Without Clinical Consequences

Jason Kahn

January 27, 2014

News Daily News

La Mala Aposición del Stent es algo Frecuente que No tiene Consecuencias Clínicas

Jason Kahn

January 27, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

Los SLF de 1ª Generación son Menos Rentables que SMD + Rapamicina Oral a los 5 Años

January 06, 2014

News Daily News

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

January 01, 2014

News Daily News

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

December 30, 2013

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

Presentation TCT 2013

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

Presenter: Ankit Garg

October 29, 2013

Advertisement

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Stent Thrombosis and Restenosis

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Mechanisms and Predictors of In-stent Restenosis and Stent Thrombosis

Lack of Association Between DAPT Use and Stent Thrombosis Between 1 and 12 Months Following Resolute ZES Implantation

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

Stent Malapposition Frequent, But Without Clinical Consequences

La Mala Aposición del Stent es algo Frecuente que No tiene Consecuencias Clínicas

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Los SLF de 1ª Generación son Menos Rentables que SMD + Rapamicina Oral a los 5 Años

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content